AC Immune SA (ACIU) –
-
AC Immune SA (ACIU) Files $350M Mixed Shelf
-
Form F-3 AC Immune SA
-
Form 6-K AC Immune SA For: Mar 14
-
Form 20-F AC Immune SA For: Dec 31
-
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
-
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
-
Form SC 13G/A AC Immune SA Filed by: AFFIRIS AG in Liqu
-
Form 6-K AC Immune SA For: Jan 22
-
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
-
Form 6-K AC Immune SA For: Jan 03
-
AC Immune SA (ACIU) Reports Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
-
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
-
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form SC 13G/A AC Immune SA Filed by: BIOTECHNOLOGY VALUE FUND L P
-
Form 6-K AC Immune SA For: Dec 19
-
Form 424B5 AC Immune SA
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
AC Immune SA (ACIU) Prices 14.3M Share Offering at $3.50/sh
-
AC Immune Announces Pricing of Underwritten Offering of Common Shares
-
AC Immune Announces Pricing of Underwritten Offering of Common Shares
-
Form 6-K AC Immune SA For: Dec 14
-
AC Immune SA (ACIU) Reports Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
-
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 6-K AC Immune SA For: Dec 01
-
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
-
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
-
Form 6-K AC Immune SA For: Nov 03
-
AC Immune SA (ACIU) Misses Q3 EPS by 21c
-
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
-
AC Immune SA (ACIU) Announces Publication Showing Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
-
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
-
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
-
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
-
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
-
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 144 AC Immune SA Filed by: Pfeifer Andrea
-
Form 6-K AC Immune SA For: Jun 30
-
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
-
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
-
Form 6-K AC Immune SA For: Jul 26
-
AC Immune SA (ACIU) Appoints Nuno Mendonça as Chief Medical Officer
-
AC Immune SA Appoints New Chief Medical Officer
Back to ACIU Stock Lookup
